Catalyst Pharmaceuticals, Inc. CPRX
Set alert
31.49 USD 0.00 0.00%
As of Jul 15, 9:30 AM ET
31.49 Day range 31.49
20.66 52-week range 32.56
- YTD
- +34.92%
- 1 year
- +43.86%
- Open
- 31.49
- Prev close
- 31.49
- Mkt cap
- 3.85B
- Vol
- 0
- Avg vol
- 2.62M
- EPS
- 1.74
- P/E
- 11.93
- Div yield
- 0.00%
More statistics
- Low
- 31.49
- High
- 31.49
- Beta
- 0.74
- Inst. own
- 90.00%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
5Y chart
Events in this range
- Mar 3, 2025Rating: Baird · Outperform → Outperform
- May 7, 2025Earnings: 0.47; estimate 0.53; surprise -11.32%
- Aug 6, 2025Earnings: 0.43; estimate 0.58; surprise -25.86%
- Nov 5, 2025Earnings: 0.43; estimate 0.51; surprise -15.69%
- Nov 7, 2025Rating: Citigroup · Buy → Buy
- Feb 25, 2026Earnings: 0.42; estimate 0.42; surprise 0%
- Mar 3, 2026Rating: Citigroup · Buy → Buy
- May 7, 2026Downgrade: Stephens & Co. · Overweight → Equal-Weight
- May 8, 2026Downgrade: Citigroup · Buy → Neutral
- May 11, 2026Earnings: 0.52; estimate 0.64; surprise -18.75%
- May 28, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (87)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Apr 28, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| SMA: Bullish | Jan 20, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 10 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 10, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 3, 2025 | 1 year ago |
| SMA: Bullish | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 8, 2025 | 1 year ago |
| SMA: Bearish | Dec 24, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 17, 2024 | 1 year ago |
| RSI: Overbought | Nov 12, 2024 | 1 year ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 17, 2024 | 2 years ago |
| MACD: Buy Signal | May 17, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 5, 2024 | 2 years ago |
| SMA: Bullish | Feb 29, 2024 | 2 years ago |
| SMA: Bullish | Feb 29, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 29, 2024 | 2 years ago |
| SMA: Bearish | Feb 8, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 8, 2024 | 2 years ago |
| SMA: Bearish | Jan 11, 2024 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 15, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 31, 2023 | 3 years ago |
| SMA: Bearish | Oct 24, 2023 | 3 years ago |
| SMA: Bullish | Oct 17, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 17, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 19, 2023 | 3 years ago |
| SMA: Bearish | Sep 5, 2023 | 3 years ago |
| SMA: Bearish | Aug 22, 2023 | 3 years ago |
| SMA: Bullish | Aug 15, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 8, 2023 | 3 years ago |
| SMA: Bullish | Jul 18, 2023 | 3 years ago |
| SMA: Bearish | May 16, 2023 | 3 years ago |
| SMA: Bearish | May 16, 2023 | 3 years ago |
| SMA: Bullish | May 2, 2023 | 3 years ago |
| SMA: Bullish | May 2, 2023 | 3 years ago |
| SMA: Bearish | Apr 25, 2023 | 3 years ago |
| SMA: Bearish | Apr 25, 2023 | 3 years ago |
| SMA: Bullish | Mar 21, 2023 | 3 years ago |
| SMA: Bullish | Mar 21, 2023 | 3 years ago |
| SMA: Bearish | Feb 28, 2023 | 3 years ago |
| SMA: Bearish | Jan 24, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 24, 2023 | 3 years ago |
| RSI: Overbought | Jan 10, 2023 | 3 years ago |
| RSI: Overbought | Dec 13, 2022 | 3 years ago |
| RSI: Overbought | Nov 22, 2022 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bearish | Oct 10, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| RSI: Overbought | Aug 1, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | May 2, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 3.85B
- Enterprise value
- 3.10B
- Trailing P/E
- 17.49
- PEG ratio
- 2.07
- Price / sales
- 6.46
- Price / book
- 3.80
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 37.08%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 23.65%
Analyst view
Price target (mean) —
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.73589.
Financials — quick view
CPRX Revenue — quarterly 149.39M
CPRX Net income — quarterly 63.73M
CPRX EPS — quarterly 0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.48 | — | — | — |
| May 11, 2026 | Mar 31, 2026 | 0.64 | 0.52 | -0.12 | -18.75% |
| Feb 25, 2026 | Dec 31, 2025 | 0.42 | 0.42 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.51 | 0.43 | -0.08 | -15.69% |
| Aug 6, 2025 | Jun 30, 2025 | 0.58 | 0.43 | -0.15 | -25.86% |
| May 7, 2025 | Mar 31, 2025 | 0.53 | 0.47 | -0.06 | -11.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| May 8, 2026 | Citigroup | down | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 7, 2025 | Citigroup | main | Buy | Buy |
| Mar 3, 2025 | Baird | main | Outperform | Outperform |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 182
- Website
- catalystpharma.com
News
- Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts
- California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
- Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
- Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
- Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026
- CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
- Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
- Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
- Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Your note
Sign in to keep a note on CPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DALY RICHARD J | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 271,266 |
| DEL CARMEN JEFFREY | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 14,337 |
| DENKHAUS DONALD A | Director | Conversion of Exercise of derivative security | Dec 28, 2025 | 498,773 |
| ELSBERND BRIAN D | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 242,501 |
| INGENITO GARY | Officer | Conversion of Exercise of derivative security | May 13, 2025 | 68,873 |
| MCENANY PATRICK JAMES | Chairman of the Board | Conversion of Exercise of derivative security | Dec 28, 2025 | 4,171,560 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.34% | 18,774,530 | 591.21M | Mar 30, 2026 |
| State Street Corporation | 5.61% | 6,863,060 | 216.12M | Mar 30, 2026 |
| Vanguard Capital Management LLC | 4.18% | 5,122,666 | 161.31M | Mar 30, 2026 |
| American Century Companies Inc | 3.38% | 4,138,416 | 130.32M | Mar 30, 2026 |
| Deerfield Management Company, L.P | 3.22% | 3,943,600 | 124.18M | Mar 30, 2026 |
| Dimensional Fund Advisors LP | 2.80% | 3,429,615 | 108.00M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.72% | 7,007,375 | 220.66M | May 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.81% | 4,670,219 | 147.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.03% | 3,711,365 | 116.87M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.43% | 2,974,227 | 93.66M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 2,759,811 | 86.91M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,287,998 | 40.56M | Mar 30, 2026 |